Kelly Mizer joined as our Vice President, Commercial Strategy and Operations in October 2021. Mr. Mizer brings nearly 20 years of experience in the biopharmaceutical industry covering multiple therapeutic areas, including rare disease and diagnostics. Prior to joining Aldeyra, he held various global and U.S. commercialization roles of increasing responsibilities at Sarepta Therapeutics, Agios Pharmaceuticals, Synageva Biopharmaceuticals (Acquired by Alexion Pharmaceuticals), BG Medicine and Eli Lilly and Company. His commercialization experience spans commercial strategy, marketing, market access, co-marketing alliances, new product planning, medical affairs and sales. Mr. Mizer also played an instrumental role in the market preparedness and subsequent launches of KANUMA® and TIBSOVO®. Mr. Mizer holds an M.S. in applied anatomy and physiology and a B.S. in human physiology from Boston University, Sargent College of Health and Rehabilitation Sciences.
Back to Leadership Team & Board of Directors